ADCX-020 / Adcytherix - LARVOL DELTA

A first-in-human, phase 1a/b study of ADCX-020, a novel integrin beta-6 targeting antibody–drug conjugate, in patients with advanced solid tumors (ESMO 2026) - No abstract available

ADC • Clinical • First-in-human • Metastases • P1 data • Oncology • Solid Tumor

ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers (clinicaltrials.gov) - P1 | N=290 | Recruiting | Sponsor: Adcytherix SAS

First-in-human • Trial initiation date • Oncology • Solid Tumor

ADCX-020-01: ADCX-020 for the treatment of patients with locally advanced or metastatic cancers (clinicaltrialsregister.eu) - P1 | N=55 | Not yet recruiting | Sponsor: Adcytherix

New P1 trial • Oncology • Solid Tumor

ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers (clinicaltrials.gov) - P1 | N=290 | Recruiting | Sponsor: Adcytherix SAS | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Oncology • Solid Tumor

ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers (clinicaltrials.gov) - P1 | N=290 | Not yet recruiting | Sponsor: Adcytherix SAS

First-in-human • New P1 trial • Oncology • Solid Tumor

French antibody biotech draws in $122M for end-of-year clinical push (FierceBiotech) - "With the new cash, the company plans to file an investigational new drug application in the U.S.—plus submit clinical trial applications in the U.K., Canada and Europe—by the end of the year for lead candidate ADCX-020."

Financing • IND • New trial • Oncology